Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days

Rhea-AI Summary

Tevogen Bio (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, has gained significant public support for its business model focused on developing accessible T cell therapeutics. The company's CEO, Dr. Saadi, expressed gratitude for the unprecedented trading volume of over half a billion shares this week. Tevogen's proprietary ExacTcell™ technology aims to create accessible, disease-specific cellular immunotherapies.

Key highlights include:

• 3 U.S. patents granted, 9 pending (including 2 for AI), and 12 international applications filed
• Positive proof-of-concept clinical trial data for the first product of its proprietary technology
• Officers hold nearly 79% of outstanding shares as of June 30, 2024
• Oncology forecast of $1 billion in launch year

Dr. Saadi reaffirmed his commitment to sharing additional progress details in the coming days.

Positive

• Positive proof-of-concept clinical trial data for first product
• 3 U.S. patents granted, 9 pending, and 12 international applications filed
• Officers hold nearly 79% of outstanding shares, demonstrating confidence
• Oncology forecast of $1 billion in launch year
• High trading volume indicating strong investor interest

Negative

• None.

Insights

Biotech Analyst

The news from Tevogen Bio is intriguing but lacks concrete financial or clinical data to make a significant impact. While the CEO's statement about unprecedented public support and high trading volume is noteworthy, it doesn't provide actionable information for investors.

The company's ExacTcell™ technology and patent portfolio show potential, but without specific details on the $1 billion oncology forecast or pipeline updates, it's difficult to assess the true value. The 79% insider ownership is significant, indicating strong confidence from management.

However, the lack of specific financial figures, detailed clinical trial results, or concrete business developments makes this news more of a teaser than a substantial update. Investors should wait for the promised additional details in the coming days before making any decisions.

WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers.

Since being founded in 2020, Tevogen Bio has taken a unique approach to both drug development and managing its business operations. The company launched is proprietary ExacTcell™ technology, designed to create accessible and disease-specific cellular immunotherapies. Tevogen Bio received 3 U.S. patents, with an additional 9 patents pending, including 2 for Artificial Intelligence, and has filed 12 international applications. Additionally, the company reported positive proof-of-concept clinical trial data for the first clinical product of its proprietary technology.

As of the quarter ending June 30, 2024, officers of Tevogen Bio held nearly 79% of the company’s outstanding shares. Any reported sales by officers were made solely to satisfy the payment of tax obligations relating to the vesting of restricted stock units and were not made at the discretion of the reporting officer. Tevogen CEO and founder, Dr. Saadi, MD, MPH, emphasized his commitment to the company’s mission of bringing accessible therapeutics to market. He noted, “The leadership team’s retention of 100% of their equity reflects their confidence in the company’s potential. With over half a billion shares traded on the open market this week, I would like to express my gratitude for this unprecedented public support for Tevogen’s business model.” Dr. Saadi added, “I was pleased that Tevogen was able to provide updates on the company, including, our pipeline, our oncology forecast of $1 billion in launch year, and I expect to continue sharing details about additional progress in the coming days.”

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.

Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen’s future clinical trials; and Tevogen’s ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com

FAQ

What is Tevogen Bio's stock symbol on Nasdaq?

Tevogen Bio's stock symbol on Nasdaq is TVGN.

How many U.S. patents has Tevogen Bio received as of October 18, 2024?

Tevogen Bio has received 3 U.S. patents as of October 18, 2024.

What is Tevogen Bio's proprietary technology called?

Tevogen Bio's proprietary technology is called ExacTcell™.

What is Tevogen Bio's oncology revenue forecast for the launch year?

Tevogen Bio forecasts $1 billion in oncology revenue for the launch year.

What percentage of Tevogen Bio's outstanding shares were held by officers as of June 30, 2024?

As of June 30, 2024, officers of Tevogen Bio held nearly 79% of the company's outstanding shares.